Jeffrey A. Schwaneke - 29 Nov 2023 Form 4/A - Amendment Insider Report for agilon health, inc. (AGL)

Signature
/s/ Mimi Yang, as Attorney-in-Fact
Issuer symbol
AGL
Transactions as of
29 Nov 2023
Net transactions value
+$250,206
Form type
4/A - Amendment
Filing time
03 Apr 2025, 19:40:25 UTC
Date Of Original Report
30 Nov 2023
Previous filing
18 Apr 2023
Next filing
31 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Purchase $250,206 +22,300 $11.22 22,300 29 Nov 2023 By trust F1, F2
transaction AGL Common Stock Award $0 +428,922 +61% $0.000000 1,130,552 01 Apr 2025 Direct F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Right to buy) Award $0 +673,077 $0.000000 673,077 01 Apr 2025 Common Stock 673,077 $4.08 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $11.12 to $11.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2 This transaction was originally reported in November 2023 and is hereby amended to clarify that the shares were purchased by and are held in the Schwaneke Family Joint Spousal Trust.
F3 Restricted stock units that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.
F4 Includes Performance Stock Units which may become vested subject to attainment (based on 40 trading day average closing price, exceeding twice the closing price of the Company's stock price on date of grant) and within three years from grant date.
F5 Includes restricted stock units.
F6 Options that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.